2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 16

Anti-Phosphatidylserine/Prothrombin Antibodies in Primary Antiphospholipid Syndrome
Abstract Number: 16L

Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Abstract Number: 17

Thrombotic Events in Pediatric Systemic Lupus Erythematosus: A Preliminary Analysis of a Large, Single-Center Cohort
Abstract Number: 17L

Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study
Abstract Number: 18

Increased Frequency of Nailfold Videocapillaroscopy Abnormalities in Primaryantiphospolipid (PAPS) Patients
Abstract Number: 18L

Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis
Abstract Number: 19

The Transcription Factor Specificity Protein 1 up-Regulates IL-21 Receptor Expression on B Cells in Rheumatoid Arthritis Leading to Altered Cytokine Production and Maturation
Abstract Number: 20

Low Molecular Weight BAFF Receptor Antagonists Restrain Infiltration of B Cells into Organs of Autoimmune Model Mice By Suppressing B Cell Activation
Abstract Number: 21

Reciprocal Regulation of B Cells on Bleomycin-Induced Scleroderma Model: IL-6-Producing Effector B Cells Play a Pathogenic Role, While IL-10-Producing Regulatory B Cells Play a Protective Role
Abstract Number: 22

Bone Regulatory Cytokine Production By B Cells in Rheumatoid Arthritis Is Dependent on NF-κb Activation and Autophagy Pathways
Abstract Number: 23

Auto-Reactive B Cells Escape Peripheral Tolerance Checkpoints in Patients with PR3-ANCA Associated Vasculitis
Abstract Number: 24

Trafficking of Innate B Cells to the Lungs As a Novel Mechanism in a Model of Pulmonary Lupus and Vasculitis
Abstract Number: 25

A Novel Role for Galectin-3 Binding Protein in B Cell Biology and Antibody Secretion
Abstract Number: 26

Single B Cell Analysis Revealed the Relationship Among the Cytokine Profile, Antibody Affinity, and Pathogenic Roles of Autoantigen-Reactive B Cells in Systemic Sclerosis
Abstract Number: 27

Effects of High Titers of Anti-Chimeric Antibodies Following Rituximab

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].